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in low rate of stent thrombosis and in-stent re-stenosis
(ISR) requiring short duration of dual anti platelet ther-
apy. Catania is neither a BMS nor a DES but somewhat
in between.
Methods: This is a prospective, single center, obser-
vational cohort study of 33 patients with symptomatic
ischemic heart disease with de novo, obstructive lesion
of native coronary arteries. The patients were followed
up at 12 months after the implantation for the symptoms
and any new coronary events.
Results: Of the 33 patients, one patient died due to
non cardiac cause, 4 patients were admitted with unsta-
ble angina and two patients with angina and positive
stress test. The entire 6 patient had significant more than
70% ISR. The target lesion revascularization (TLR) at 12
months was 18.75%
Conclusion: At one year follow up, The Catania stent
was found to be associated with a significant ISR with
TLR of 18.75%.
http://dx.doi:10.1016/j.jsha.2013.03.052
Recombinant activated factor VII (rFVIIa) for un-
controlled bleeding post cardiac surgery
Aly Makram Habib, Ahmed Yehia Mousa,
Zohair Yousif Al Halees
Objectives: To review recombinant activated factor
VII (rFVIIa) as rescue therapy in persistent severe hemor-
rhage in post cardiac surgical patients at our institution.
Design: A retrospective observational study.
Patients and methods: From 2004 till April 2010, all
patients who received rFVIIa for bleeding of 3 ml/kg/h or
more for two consecutive hours after cardiac surgery
were included. Surgical bleeding management, patient
temperature correction, blood products replacement,
and coagulant drugs administration preceded the rFVIIa.
Results: The mean for chest tube drainage was sig-
nificantly lower after the administration of rFVIIa com-
pared to that before (1.2 ± 1.08 vs. 4.1 ± 2.3 ml/kg/h,
P = 0.042). There was a significant decrease in the median
of: aPTT (43.8 vs. 46.6 s, P = 0.027), ACT (128.9 vs. 131.7 s,
P = 0.05), and INR (1.0 vs. 1.43, P = 0.001) after the admin-
istration of rFVIIa compared to that before. The median
of fibrinogen level and the platelet count showed non-
significant increase after the rFVIIa doses (2.57 vs.
2.43 gm/l, P = 0.34 and 106 vs. 101 X109/l, P = 0.27 respec-
tively). Six patients (3.7%) needed re-exploration after the
administration of rFVIIa. Five patients (3.2%) had
thrombo-embolic complications. The small dose (40–
50 mcg/kg) was comparable to high dose (P80 mcg/kg)
of rFVIIa in terms of: mean chest tube bleeding within
the first 4 h, blood products required in the first 24 h,
re-exploration for bleeding or thrombotic complications.
Conclusion: rFVIIa produced significant reduction in
chest tube bleeding post cardiac surgery with reduction
in the administration of blood products. Small dose
rFVIIa can be considered effective for intractable bleed-
ing after cardiac surgery.
http://dx.doi:10.1016/j.jsha.2013.03.053
Mid-term outcome of extracardiac Fontan opera-
tion using Contegra conduit
Deraz Al Sayed Salem, Arfi Muhammed Amin,
Sharfi Hussain Masroor, Fouad Ismail Muhamed,
Baslaim Ghassan, Hussain Arif
Background: Limited surgical experience of con-
structing Fontan circulation using Contegra conduit has
raised concerns of high risk of thrombotic occlusion of
Fontan circuit.In this study we intended to retrospec-
tively evaluate thrombotic complication and survival of
patients undergone extra-cardiac Fontan procedure.
Methods: Medical records of all patients who under-
went Fontan completion from January 2002 to December
2010 were reviewed. Echocardiographic, catheterization,
and peri-operative data were recorded. Outcome of Fon-
tan procedure using Contegra conduit was compared
with those constructed with Dacron tube. All patients
received anticoagulation using heparin in the immediate
postoperative period and later on Coumadin to maintain
therapeutic level of INR. The primary outcome was the
prevalence of thrombotic complication and the survival
in the two groups. Chi-square was used to compare the
categorical variables. Independent 2 sample t-test was
used to compare the pre-operative and postoperative
numerical variables in the two groups and Kaplan meier
curve and Log Rank test were generated to compare the
time interval of the two primary outcomes of the two
groups.
Results: Seventy-six patients underwent Fontan pro-
cedure, using Contegra (n = 47) and Dacron tube (n = 29).
The two groups matched with regard to demographic
variables, preoperative hemodynamic data, intra-opera-
tive and post-operative outcome. Thrombotic complica-
tions occurred within the first 30 days in 6/47 (13%) in
Contegra and 3/29 (10%) in Dacron group and the differ-
ence was not significant (p = 0.983). Relative risk of
thrombosis in Contegra group was 0.949 (95% CI = 0.8–
1.3). The mean follow up for the whole group was 87
months. The mean follow up for Contegra group was 70
months and 95 months for the Dacron group but this dif-
ference was not significant (p = 0.304). Nine patients died:
Contegra 7/47, Dacron, 2/28 (p = 0.486). Relative risk of
dying in Contegra group was 0.909 (95% CI = 0.8–1.1).
Conclusion: This is the largest series evaluating the
outcome of extra-cardiac Fontan procedure using Conte-
gra conduit. Our results suggest that using Contegra con-
duit does not increase the risk of thrombotic complication
or death compared to Fontan completion using Dacron
tube.
http://dx.doi:10.1016/j.jsha.2013.03.057
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